Research evidences explained the role of angiogenesis triggered by inflammation in NAFLD pathogenesis and highlighted potential of targeting VEGF to treat NAFLD (Lei et al., 2021). This evidence concerns the gene VEGFA and metabolic dysfunction-associated steatotic liver disease.